PubRank

T J Montine

Author PubWeight™ 66.61‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013 9.46
2 CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 2007 4.24
3 Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 2007 3.67
4 Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 1999 2.31
5 Neural transplantation in Huntington disease: long-term grafts in two patients. Neurology 2007 2.15
6 Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 1998 1.71
7 Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. J Neuropathol Exp Neurol 2000 1.63
8 Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 2005 1.56
9 A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology. Brain 2007 1.40
10 The lipid peroxidation product 4-hydroxynonenal inhibits neurite outgrowth, disrupts neuronal microtubules, and modifies cellular tubulin. J Neurochem 1999 1.32
11 Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Am J Pathol 2001 1.26
12 Proteasomal inhibition induced by manganese ethylene-bis-dithiocarbamate: relevance to Parkinson's disease. Neuroscience 2004 1.17
13 Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. Am J Pathol 1997 1.16
14 4-Hydroxy-2(E)-nonenal inhibits CNS mitochondrial respiration at multiple sites. J Neurochem 1999 1.12
15 Formation of novel D-ring and E-ring isoprostane-like compounds (D4/E4-neuroprostanes) in vivo from docosahexaenoic acid. Biochemistry 2000 1.09
16 Herpes simplex virus type 1 latency in the murine nervous system is associated with oxidative damage to neurons. Virology 2000 1.09
17 Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Neurology 2010 1.07
18 Enhanced N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase. J Neuropathol Exp Neurol 2000 1.06
19 Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype. J Neuropathol Exp Neurol 1998 1.02
20 Acrolein inhibits respiration in isolated brain mitochondria. Biochim Biophys Acta 2001 0.98
21 Improved assay for the quantification of the major urinary metabolite of the isoprostane 15-F(2t)-Isoprostane (8-iso-PGF(2alpha)) by a stable isotope dilution mass spectrometric assay. Clin Chim Acta 2001 0.95
22 4-hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J Neuropathol Exp Neurol 1997 0.95
23 Massive pulmonary embolus and anabolic steroid abuse. JAMA 1992 0.94
24 Lack of cerebral bmaa in human cerebral cortex. Neurology 2009 0.93
25 Selective dendritic degeneration of medium spiny neurons in dementia with Lewy bodies. Neurology 2006 0.93
26 Impaired cognition, sensorimotor gating, and hippocampal long-term depression in mice lacking the prostaglandin E2 EP2 receptor. Exp Neurol 2009 0.92
27 Lipoproteins and lipid peroxidation in Alzheimer's disease. J Nutr Health Aging 2003 0.89
28 Formation of highly reactive gamma-ketoaldehydes (neuroketals) as products of the neuroprostane pathway. J Biol Chem 2001 0.89
29 No difference in plasma or urinary F2-isoprostanes among patients with Huntington's disease or Alzheimer's disease and controls. Ann Neurol 2000 0.89
30 Expression and activities of aldo-keto oxidoreductases in Alzheimer disease. J Neuropathol Exp Neurol 2001 0.88
31 Elevation of AKR7A2 (succinic semialdehyde reductase) in neurodegenerative disease. Brain Res 2001 0.86
32 Cerebrospinal fluid lipoproteins are more vulnerable to oxidation in Alzheimer's disease and are neurotoxic when oxidized ex vivo. Lipids 1999 0.85
33 Enhancement of dopaminergic neurotoxicity by the mercapturate of dopamine: relevance to Parkinson's disease. J Neurochem 2000 0.85
34 A valid experimental brain death organ donor model. J Heart Lung Transplant 1995 0.83
35 Neuronal migration disorders: positron emission tomography correlations. Ann Neurol 1994 0.83
36 Secondary excitotoxicity contributes to dopamine-induced apoptosis of dopaminergic neuronal cultures. Biochem Biophys Res Commun 1998 0.82
37 Reactions of 4-hydroxy-2(E)-nonenal and related aldehydes with proteins studied by carbon-13 nuclear magnetic resonance spectroscopy. Chem Res Toxicol 1998 0.82
38 High-pressure liquid chromatography quantitation of cytochrome c using 393 nm detection. Anal Biochem 1999 0.82
39 Fragile X gene premutation in multiple system atrophy. J Neurol Sci 2004 0.82
40 Wernicke's encephalopathy in a patient with AIDS. AIDS 1993 0.81
41 Apolipoprotein E allelic influence on human cerebrospinal fluid apolipoproteins. J Lipid Res 1998 0.81
42 Expression of glutathione-S-transferase isozyme in the SY5Y neuroblastoma cell line increases resistance to oxidative stress. Free Radic Biol Med 2001 0.80
43 Human, but not bovine, oxidized cerebral spinal fluid lipoproteins disrupt neuronal microtubules. Lipids 2000 0.78
44 Dopamine thioethers in neurodegeneration. Curr Top Med Chem 2001 0.78
45 The mitochondrial common deletion in Parkinson's disease and related movement disorders. Parkinsonism Relat Disord 2002 0.78
46 Interactions between apolipoprotein E gene and dietary alpha-tocopherol influence cerebral oxidative damage in aged mice. J Neurosci 2001 0.77
47 Quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Adv Exp Med Biol 2001 0.77
48 Alpha-methylserotonin, a substitute transmitter for serotonergic neurons. Prog Neuropsychopharmacol Biol Psychiatry 1990 0.77
49 CSF lipoproteins and Alzheimer's disease. J Nutr Health Aging 2002 0.76
50 Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 2000 0.76
51 Cerebrospinal fluid lipoproteins in Alzheimer's disease. Microsc Res Tech 2000 0.76
52 Congeners of N(alpha)-acetyl-L-cysteine but not aminoguanidine act as neuroprotectants from the lipid peroxidation product 4-hydroxy-2-nonenal. Free Radic Biol Med 2000 0.76
53 Pathologic assessment of cerebellar atrophy following acute lithium intoxication. Clin Neuropathol 1997 0.76
54 Endogenous catechol thioethers may be pro-oxidant or antioxidant. Free Radic Biol Med 1999 0.75
55 High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: preliminary pharmacologic observations. Cancer Chemother Pharmacol 1989 0.75
56 Cysteine and mercapturate conjugates of oxidized dopamine are in human striatum but only the cysteine conjugate impedes dopamine trafficking in vitro and in vivo. J Neurochem 2001 0.75
57 Formation of novel isoprostane-like compounds from docosahexaenoic acid. Adv Exp Med Biol 1999 0.75
58 Renal toxicity of antineoplastic agents. Toxicol Lett 1990 0.75
59 Divergence of brain prostaglandin H synthase activity and oxidative damage in mice with encephalitis. J Neuropathol Exp Neurol 1999 0.75